HBIO
NASDAQHarvard Bioscience Inc.
Price$6.20+0.66 (+11.99%)
2026-03-062026-06-09
News · 26 weeks42-78%
2025-12-142026-06-07
Mix2190d
- SEC Filings9(43%)
- Insider6(29%)
- Earnings3(14%)
- Other3(14%)
Latest news
25 items- SECHarvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form SD filed by Harvard Bioscience Inc.SD - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
- SECSEC Form 10-Q filed by Harvard Bioscience Inc.10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- PRHarvard Bioscience Announces First Quarter 2026 Financial ResultsFirst Quarter 2026 Revenues of $20.8M and Gross Margin of 59%Consolidation of Manufacturing Operations Progressing on ScheduleReaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the first quarter ended March 31, 2026. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said John Duke, President and Chief Executive Officer. "We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA™ organoid pla
- PRHarvard Bioscience to Participate in Upcoming Investor ConferencesHOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events. Sidoti Micro Cap Conference Location: VirtualDate: Thursday, May 21, 2026Fireside Chat Presentation: 11:30 AM ET Benchmark (StoneX) Healthcare House Call Virtual Conference Location: VirtualDate: Thursday, May 28, 2026 A live webcast of the Sidoti fireside chat will be made available on Harvard Bioscience's Investor Relations website. An archived replay of the webcast will be available following the event. About Harvard Bioscience Harvard Bioscienc
- PRHarvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ETHOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wil
- SECSEC Form DEFA14A filed by Harvard Bioscience Inc.DEFA14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form DEF 14A filed by Harvard Bioscience Inc.DEF 14A - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- INSIDERSEC Form 4 filed by Frost Mark T4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Frost Mark T4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Duke John D4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Denelsky Stephen J4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERSEC Form 4 filed by Snider William4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- INSIDERChief Executive Officer Duke John D bought $25,050 worth of shares (5,000 units at $5.01), increasing direct ownership by 5% to 105,000 units (SEC Form 4)4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECSEC Form 10-K filed by Harvard Bioscience Inc.10-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- PRHarvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial ResultsFourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- SECHarvard Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
- PRHarvard Bioscience Announces Reverse Stock SplitHarvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced that its board of directors approved the Company's 1-for-10 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.01 per share. The Reverse Split was approved by the stockholders of the Company at a special meeting held on March 6, 2026. The Reverse Split will legally take effect at 4:30 p.m. Eastern Time, on March 13, 2026. The Reverse Split is intende
- PRHarvard Bioscience to Participate in KeyBanc's Virtual Healthcare ForumHOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets' Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company's investor relations website at 2:15pm ET that day. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. About Harvard Bioscience Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable
HBIO FAQ
7 questionsWhat does Harvard Bioscience Inc. do?
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion...Where does HBIO stock trade?
Harvard Bioscience Inc. (HBIO) is listed on NASDAQ.What sector and industry is HBIO in?
Harvard Bioscience Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Harvard Bioscience Inc. go public?
Harvard Bioscience Inc. (HBIO) completed its IPO in 2000.What are analysts saying about HBIO?
Harvard Bioscience Inc. has had 2 recent analyst actions on file. The most recent action was from KeyBanc Capital Markets: Sector Weight on 2025-04-09. Recent price targets cluster around $400.00.What companies are similar to HBIO?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare HBIO side-by-side with any of them on Quantisnow.How can I track HBIO on Quantisnow?
Quantisnow aggregates Harvard Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HBIO to receive live email and push alerts on every new disclosure.